

Board of Directors Meeting in Public - Cover Sheet

| | | | | |
|--|--|---|--|--------------------------------|
| Subject: | Research and Development Annual Update Q4 2018/19 | Date: 4th July 2019 | | |
| Prepared By: | Alison Steel, Head of Research and Innovation | | | |
| Approved By: | David Hodgson, Research and Innovation Director | | | |
| Presented By: | Alison Steel, Head of Research and Innovation | | | |
| Purpose | | | | |
| Summary of R&I metrics and benchmarking performance (Q4) | | Approval | | |
| Assurance of financial position at Q4 | | Assurance | X | |
| Patient Experience | | Update | | |
| Communication and Engagement | | Consider | | |
| Outline of 2019/20 Strategic Priorities | | | | |
| Strategic Objectives | | | | |
| To provide outstanding care | To promote and support health and wellbeing | To maximise the potential of our workforce | To continuously learn and improve | To achieve better value |
| X | | | X | X |
| Overall Level of Assurance | | | | |
| | Significant | Sufficient | Limited | None |
| | | X | | |
| Risks/Issues | | | | |
| Financial | <ul style="list-style-type: none"> Confirmed £713,387.00 EMCRN budget, a small decrease of 0.2% on 18/19, excl NHS pay award Commercial income for re-investment £63,800 | | | |
| Patient Impact | 197 participants took part in patient experience survey 2018/19 with an average satisfaction score of 96.8% | | | |
| Staff Impact | <ul style="list-style-type: none"> Currently appointing to the SFH Research academy Funding provided to support an ED and critical care nurse to assist with the delivery of research out of hours | | | |
| Services | Currently have a strong reputation for research delivery across the region and have been praised for strengths in financial probity, overall recruitment and recruitment to time and target by the EMCRN. | | | |
| Reputational | | | | |
| Committees/groups where this item has been presented before | | | | |
| PSQG in June 2019 | | | | |
| Executive Summary | | | | |
| <p>Recruitment performance in Research and Innovation at SFH continues to increase. Q4 performance 2018/19:</p> <ol style="list-style-type: none"> 2121 participants recruited in 18/19 c.f to 1625 in 17/18, 31% increase 100% of annual target achieved by October 2018. 71 studies are open at SFH with 65 actively recruiting | | | | |

4. 100%of commercial and 80% of non-commercial studies are recruiting to 100% time and target
5. Trials are spread across most specialities in the organisation with more clinical research activity being conducted in the areas of Cancer, Cardiovascular disease, Gastroenterology, Reproductive Health and Childbirth and Stroke. New areas opening studies e.g , Critical Care and Emergency Department
6. **Dashboard provides visual display of Q4 KPI's and key data**